[The somatostatin analog SMA (201-995) as adjuvant treatment in patients with external fistulae of the digestive system].
Six patients with gastrointestinal fistulae treated with a potent inhibitor of gastrointestinal hormones, the somatostatin analogue SMS 201-995 are reported. All patients had severe intraabdominal diseases and underwent a mean of 3.5 surgery procedures during their hospital stay. When the patients were analyzed individually a mean reduction of 42.5% (P < 0.050 of basal fistulae output was observed after treatment. In three patients the fistulae closed after seven and ten days of treatment with the analogue; the other three patients died after a protracted hospital stay which included multiple admissions to the Intensive Care Unit. When the output of all fistulae treated where analyzed together it showed a tendency to decrease, but it didn't reach statistical significance.
Castañón González
J A
JA
Unidad de Cuidados Intensivos, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS.
Miranda Ruíz
R
R
Arías
E
E
Fuentes Pintado
E
E
Zárate Treviño
A
A
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001658:Biliary Fistula / Q000188:drug therapy* / Q000453:epidemiology; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy* / Q000453:epidemiology; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010185:Pancreatic Fistula / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies
D015282:Octreotide
El análogo de somatostatina SMS (201-995) como tratamiento adyuvante en pacientes con fístulas externas del aparato digestivo.